



Fig. S1. Comparison of clinical severity, steroid requirements, and acral predilection among 3 groups. (a) Autoimmune Bullous Skin Disorder Intensity Scores (ABSIS) and (b) Bullous Pemphigoid Disease Area Index (BPDAl) scores in idiopathic bullous pemphigoid group (IDIOPATHIC) and patients with immunotherapy-associated bullous pemphigoid (BP) induced by anti-PD-1/PD-L1 monotherapy (MONO) or a transforming growth factor-beta inhibitor (TGFβi) combination regimen (COMBO). (c) Peak and (d) lowest maintenance steroid dosages (mg/kg/day) required to treat BP activity. (e) Clinical severity of hand and foot involvement.